 |
|
Pancreatic Cancer Trial Results
1. Gemcitabine Plus Standard Chemoradiation Improves Survival in Patients with Pancreatic Head Tumors
(Posted: 06/05/2006) - Adding gemcitabine to a standard chemoradiation regimen improved overall survival in patients with the most common kind of pancreatic tumors: those located in the head of the pancreas, according to findings presented at the 2006 meeting of the American Society of Clinical Oncology.
2. Erlotinib Plus Gemcitabine Boosts One-Year Survival in Pancreatic Cancer
(Posted: 05/14/2005, Reviewed: 10/06/2007) - Patients with advanced pancreatic cancer who were treated with the drug erlotinib (Tarceva®) in addition to gemcitabine had modest improvement in one-year survival rates compared to patients treated with gemcitabine alone, according to findings presented at the 2005 meeting of the American Society of Clinical Oncology.
3. Post-Surgery Gemcitabine Delays Recurrence of Pancreatic Cancer
(Posted: 05/14/2005, Reviewed: 01/23/2007) - Patients with operable pancreatic cancer who got additional therapy with the drug gemcitabine lived nearly twice as long before their disease recurred as patients who were treated with surgery alone, according to findings presented at the 2005 meeting of the American Society of Clinical Oncology.
|
|
|
